Holen Sie sich die Stockscreener-App
11.82
1.55%
0.18
Handel nachbörslich:
11.97
0.15
+1.27%
Schlusskurs vom Vortag:
$11.64
Offen:
$11.8
24-Stunden-Volumen:
1.47M
Relative Volume:
1.30
Marktkapitalisierung:
$838.55M
Einnahmen:
$114.04M
Nettoeinkommen (Verlust:
$-330.15M
KGV:
-2.4989
EPS:
-4.73
Netto-Cashflow:
$-274.85M
1W Leistung:
-3.19%
1M Leistung:
-4.06%
6M Leistung:
+187.59%
1J Leistung:
-24.76%
1-Tages-Spanne:
$11.27
$12.32
1-Wochen-Bereich:
$10.33
$12.98
52-Wochen-Spanne:
$2.21
$19.50
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Vergleichen Sie PHAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
11.82 | 825.78M | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Will Phathom Pharmaceuticals Inc. continue its uptrendDay Trade & AI Powered Market Trend Analysis - newser.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Is Phathom Pharmaceuticals Inc. meeting your algorithmic filter criteriaJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
Leading vs lagging indicators on Phathom Pharmaceuticals Inc. performanceMarket Performance Report & Long-Term Capital Growth Strategies - newser.com
Why hedge funds are buying Phathom Pharmaceuticals Inc. stockJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com
Statistical indicators supporting Phathom Pharmaceuticals Inc.’s strength2025 Price Action Summary & Breakout Confirmation Alerts - newser.com
Phathom Pharmaceuticals Hits Day Low of $10.33 Amid Price Pressure - Markets Mojo
When Will Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Breakeven? - simplywall.st
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 7.8%Here's What Happened - MarketBeat
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer - citybiz
Phathom Pharmaceuticals, Inc. Appoints Sanjeev Narula as Chief Financial and Business Officer - MarketScreener
When is the best time to exit Phathom Pharmaceuticals Inc.Global Markets & Expert Approved Trade Ideas - newser.com
Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer - Investing.com
Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals Appoints New Chief Financial Officer - TipRanks
Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial and business officer - Investing.com
Using Bollinger Bands to evaluate Phathom Pharmaceuticals Inc.2025 Technical Overview & Stock Portfolio Risk Management - newser.com
Analyzing recovery setups for Phathom Pharmaceuticals Inc. investorsSwing Trade & Long-Term Safe Investment Ideas - newser.com
Will Phathom Pharmaceuticals Inc. see short term momentumQuarterly Growth Report & Low Drawdown Trading Strategies - newser.com
Tools to monitor Phathom Pharmaceuticals Inc. recovery probabilityJuly 2025 Summary & Safe Capital Preservation Plans - newser.com
How to integrate Phathom Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Closing Moves & Smart Swing Trading Alerts - newser.com
How Phathom Pharmaceuticals Inc. stock reacts to Fed rate cutsQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
What Fibonacci levels say about Phathom Pharmaceuticals Inc. reboundMarket Risk Report & Daily Stock Momentum Reports - newser.com
How to build a custom watchlist for Phathom Pharmaceuticals Inc.July 2025 Decliners & Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-02 20:30:06 - newser.com
Phathom Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators - Markets Mojo
Published on: 2025-10-01 09:34:59 - newser.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 5.5%Still a Buy? - MarketBeat
Published on: 2025-09-30 02:22:28 - newser.com
Phathom Pharmaceuticals Inc Stock Analysis and ForecastValue Stock Picks & Affordable Trading Growth - earlytimes.in
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
| Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
| Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):